Suppression of soft tissue sarcoma growth by a host defense-like lytic peptide

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Steinstraesser, Lars ^a   Hauk, Jennifer ^a   Schubert, Cornelius ^a   Al Benna, Sammy ^a   Stricker, Ingo ^a   Hatt, Hanns ^b   Shai, Yechiel ^c   Steinau, Hans Ulrich ^a   Jacobsen, Frank ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BROXURIDINE; DEXTRO LEUCYLHISTIDYLLEUCYLLEUCYLHISTIDYLLYSYLLEUCYLLEUCYLLYSYLHISTIDYLLEUCYLLEUCYLLYSYLLEUCYLLEUCINAMIDE; UNCLASSIFIED DRUG; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL GROWTH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG RESPONSE; HEMOLYSIS; HISTOPATHOLOGY; HOST RESISTANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE DAMAGE; MOUSE; NICK END LABELING; NONHUMAN; SCANNING ELECTRON MICROSCOPY; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL SURVIVAL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; PH; SARCOMA; SOFT TISSUE TUMOR; TUMOR CELL LINE;

MURINAE; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; DNA FRAGMENTATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMOLYSIS; HUMANS; HYDROGEN-ION CONCENTRATION; MICE; MICE, INBRED BALB C; PEPTIDES; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 79953672210     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018321     Document Type: Article

References (39)

1. Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, et al. (2002) Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 359: 1301-1307.
2. Eilber FC, Eilber FR, Eckardt J, Rosen G, Riedel E, et al. (2004) The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg 240: 686-695; discussion 695-687.
3. Chao C, McMasters KM, Edwards MJ, (2002) Advances in the treatment of soft-tissue sarcomas. J Ky Med Assoc 100: 10-16.
4. Al-Benna S, Steinstrasser L, (2009) Postablative reconstruction is better terminology than oncoplastic surgery. Plast Reconstr Surg 124: 463e-464e.
5. Reichardt P, (2002) High-dose chemotherapy in adult soft tissue sarcoma. Crit Rev Oncol Hematol 41: 157-167.
6. Steinau HU, Homann HH, Drucke D, Torres A, Soimaru D, et al. (2001) [Resection method and functional restoration in soft tissue sarcomas of the extremities]. Chirurg 72: 501-513.
7. Billingsley KG, Burt ME, Jara E, Ginsberg RJ, Woodruff JM, et al. (1999) Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg 229: 602-610; discussion 610-602.
8. Cormier JN, Huang X, Xing Y, Thall PF, Wang X, et al. (2004) Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol 22: 4567-4574.
9. Moscow JA, Schneider E, Ivy SP, Cowan KH, (1997) Multidrug resistance. Cancer Chemother Biol Response Modif 17: 139-177.
10. Steinstraesser L, Kraneburg UM, Hirsch T, Kesting M, Steinau HU, et al. (2009) Host defense peptides as effector molecules of the innate immune response: a sledgehammer for drug resistance? Int J Mol Sci 10: 3951-3970.
11. Papo N, Shai Y, (2005) Host defense peptides as new weapons in cancer treatment. Cell Mol Life Sci 62: 784-790.
12. Baker MA, Maloy WL, Zasloff M, Jacob LS, (1993) Anticancer efficacy of Magainin2 and analogue peptides. Cancer Res 53: 3052-3057.
13. Lehmann J, Retz M, Sidhu SS, Suttmann H, Sell M, et al. (2006) Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cell lines. Eur Urol 50: 141-147.
14. Steinstraesser L, Kraneburg UM, Jacobsen F, Al-Benna S, (in press) Host Defense Peptides and their antimicrobial-immunomodulatory duality. Immunobiology.
15. Boman HG, (1995) Peptide antibiotics and their role in innate immunity. Annu Rev Immunol 13: 61-92.
16. Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA, (1999) Phylogenetic perspectives in innate immunity. Science 284: 1313-1318.
17. Lehrer RI, Ganz T, (1999) Antimicrobial peptides in mammalian and insect host defence. Curr Opin Immunol 11: 23-27.
18. Oren Z, Shai Y, (1997) Selective lysis of bacteria but not mammalian cells by diastereomers of melittin: structure-function study. Biochemistry 36: 1826-1835.
19. Papo N, Braunstein A, Eshhar Z, Shai Y, (2004) Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino Acid Peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion. Cancer Res 64: 5779-5786.
20. Pan JG, Mak TW, (2007) Metabolic targeting as an anticancer strategy: dawn of a new era? Sci STKE 2007: pe14.
21. Tannock IF, Rotin D, (1989) Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 49: 4373-4384.
22. Vaupel P, Kallinowski F, Okunieff P, (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449-6465.
23. Makovitzki A, Fink A, Shai Y, (2009) Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides. Cancer Res 69: 3458-3463.
24. Kokryakov VN, Harwig SS, Panyutich EA, Shevchenko AA, Aleshina GM, et al. (1993) Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins. FEBS Lett 327: 231-236.
25. Steinstraesser L, Jacobsen F, Schubert C, Gevers K, Stricker I, et al. (in press) Establishment of a Primary Human Sarcoma Model in Athymic Nude Mice. Hum Cell.
26. Hirsch T, von Peter S, Dubin G, Mittler D, Jacobsen F, et al. (2006) Adenoviral gene delivery to primary human cutaneous cells and burn wounds. Mol Med 12: 199-207.
27. Radzishevsky IS, Rotem S, Bourdetsky D, Navon-Venezia S, Carmeli Y, et al. (2007) Improved antimicrobial peptides based on acyl-lysine oligomers. Nat Biotechnol 25: 657-659.
28. Papo N, Shahar M, Eisenbach L, Shai Y, (2003) A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and in mice. J Biol Chem 278: 21018-21023.
29. Momparler RL, Karon M, Siegel SE, Avila F, (1976) Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res 36: 2891-2895.
30. Zachowski A, (1993) Phospholipids in animal eukaryotic membranes: transverse asymmetry and movement. Biochem J 294 (Pt 1): 1-14.
31. Dennison SR, Whittaker M, Harris F, Phoenix DA, (2006) Anticancer alpha-helical peptides and structure/function relationships underpinning their interactions with tumour cell membranes. Curr Protein Pept Sci 7: 487-499.
32. Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ, (1991) Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 51: 3062-3066.
33. Zasloff M, (2002) Antimicrobial peptides of multicellular organisms. Nature 415: 389-395.
34. Bergers G, Hanahan D, (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603.
35. Saenz NC, Heslin MJ, Adsay V, Lewis JJ, Leung DH, et al. (1998) Neovascularity and clinical outcome in high-grade extremity soft tissue sarcomas. Ann Surg Oncol 5: 48-53.
36. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, et al. (2009) Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 27: 3126-3132.
37. Kuenen BC, Tabernero J, Baselga J, Cavalli F, Pfanner E, et al. (2003) Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 9: 1648-1655.
38. Benkirane N, Friede M, Guichard G, Briand JP, Van Regenmortel MH, et al. (1993) Antigenicity and immunogenicity of modified synthetic peptides containing D-amino acid residues. Antibodies to a D-enantiomer do recognize the parent L-hexapeptide and reciprocally. J Biol Chem 268: 26279-26285.
39. Lins L, Charloteaux B, Heinen C, Thomas A, Brasseur R, (2006) "De novo" design of peptides with specific lipid-binding properties. Biophys J 90: 470-479.